NCT01214343Unknown3 期
Randomized Controlled Trial Comparing Efficacy of Sorafenib Versus Sorafenib In Combination With Low Dose Cisplatin /Fluorouracil Hepatic Arterial InfUSion Chemotherapy in Patients With Advanced Hepatocellular Carcinoma
Ministry of Health, Labour and Welfare, Japan30 个研究点 分布在 1 个国家目标入组 190 人开始时间: 2010年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 190
- 试验地点
- 30
- 主要终点
- Overall survival
研究概览
简要总结
The purpose of this study is to evaluate the efficacy of sorafenib in combination with low dose cisplatin /fluorouracil hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma.
详细描述
Sorafenib with Low-dose FP Group
Sorafenib will be administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid) for 28 days. Cisplatin at the dose of 20mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 330mg/m2 will be administered continuously at day1-day5, and day8-day12 via the implanted catheter system.
Sorafenib Group
Sorafenib will be administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid) for 28 days.
The treatment regimen will be continued until radiographic or symptomatic progression, the development of unacceptable toxicity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •20 Years and older.
- •Life expectancy of at least 12 weeks at the pre-treatment evaluation.
- •Advanced hepatocellular carcinoma with histological evidence on a biopsy specimen, or typical findings by dynamic CT or CT during hepatic arteriography/arterioportography.
- •Not suitable for resection or local ablation therapy or transcatheter arterial chemoembolization.
- •ECOG Performance status of 0 or
- •Cirrhotic status of Child-Pugh score ≤
- •Adequate bone marrow, liver and renal function, as assessed by the following laboratory requirements:
- •Hemoglobin ≥8.5 g/dl
- •Granulocytes≥1500/μL
- •Platelet count ≥50,000 /μL
- •PT-INR ≤ 2.3
- •Total serum bilirubin ≤ 2 mg/dl
- •AST(SGOT) and ALT(SGPT) ≤ 6 × upper limit of normal
- •Serum creatinine ≤ 1.5 × upper limit of normal
- •Amylase ≤ 2 × upper limit of normal
- •Written Informed Consent must be obtained.
排除标准
- •Previous malignancy (except for cervical carcinoma in situ, adequate treated basal cell carcinoma, or superficial bladder tumors [Ta, Tis and T1], early gastric cancer, or other malignancies curatively treated > 3 years prior to entry
- •Renal failure
- •Any heart disease as follows
- •Congestive heart failure defined as NYHA class III or IV
- •Active coronary artery disease or ischemic heart disease such as cardiac infarction within 6 months prior to screening
- •Serious cardiac arrhythmia
- •Serious hypertension
- •Active clinically serious infections except for HBV and HCV
- •Active chicken pox.
- •Auditory disorder.
- •Known history of HIV infection.
- •Known metastatic or meningeal tumors.
- •Extrahepatic tumor spread which affects patient's prognosis
- •History of seizure disorder.
- •Clinically significant gastrointestinal bleeding within 4 weeks prior to study entry.
- •Embolization or infarction such as transient ischemic disease, deep vein thrombosis, pulmonary embolization.
- •Any history of treatment as follows:
- •Treatment with the agent which induces CYP3A4
- •Surgical procedure within 4 weeks prior to start of study drug
- •History of organ allograft
- •Patients unable to swallow oral medications.
- •Gastrointestinal disease that may affect to the absorption of drug or pharmacokinetics.
- •Medication that may affect to the absorption of drug or pharmacokinetics.
- •Any disease or disorder that may affect the evaluation of study drug.
- •Entry to the other clinical trial within 4 weeks prior to entry to this study.
- •Pregnant or breast-feeding patients.
- •Known allergy to the investigational agent or any agent given in association with this trial.
- •Substance abuse, medical, psychological or social conditions that, in the judgment of the investigator, is likely to interfere with the patient's participation in the study or evaluation of the stuy results.
- •Any condition that is unstable or could jeopardize the safety of the patient and its compliance in the study, in the investigator's judgment.
研究组 & 干预措施
Sorafenib with Low-dose FP
Experimental
干预措施: Sorafenib with Low-dose FP (Drug)
Sorafenib
Active Comparator
干预措施: Sorafenib (Drug)
结局指标
主要结局
Overall survival
时间窗: Overall survival is defined as the time from randomization to death due to any cause
次要结局
- Time to progression(TTP is defined as the time from randomization to radiological progression.)
- Progression Free Survival(PFS is defined as the time from randomization to radiological progression or death due to any cause)
- Change of tumor marker(Every 4-6 weeks)
- Biomarker predicting the efficacy(Pre and after treatment)
研究者
研究点 (30)
Loading locations...
相似试验
已完成
2 期
Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular CancerHepatocellular CancerNCT00813293Beth Israel Deaconess Medical Center20
终止
不适用
Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular CarcinomaHepatocellular CarcinomaNCT02748304Fudan University52
Unknown
2 期
Sorafenib Combined With Arsenical in Treating Patients With Recurrent HCC After Liver TransplantationHCCNCT04232722Zhejiang University43
已完成
3 期
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast CancerBreast CancerNCT01234337Bayer537
已完成
2 期
Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation: STARGATEMalignant Neoplasm of StomachEffects of ChemotherapyNCT01187212Asan Medical Center195